References in periodicals archive ?
The phase 1 clinical trial of PWT33597 is a single agent study designed to evaluate the safety of escalating doses of PWT33597 in patients with advanced solid tumors.
An earlier Phase 3 single agent study of GV1001 in pancreatic cancer was reported to have been halted after a preliminary analysis showed no survival benefit.
Interim results from the ongoing Phase 1 single agent study of CAL-101 in patients with relapsed or refractory hematologic malignancies have demonstrated overall response rates of 71 percent, 75 percent, and 29 percent for patients with indolent NHL, mantle cell lymphoma, and CLL, respectively.
If the data are positive in the ongoing GRN163L single agent study in multiple myeloma, we plan to pursue a pivotal registration trial in that indication.